Senseonics (NYSE:SENS) Hits New 52-Week High – What’s Next?

Senseonics Holdings, Inc. (NYSE:SENS)’s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $1.20 and last traded at $1.19, with a volume of 3529592 shares. The stock had previously closed at $1.10.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. StockNews.com assumed coverage on Senseonics in a research note on Thursday, December 26th. They issued a “sell” rating for the company. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Price Performance

The stock has a 50 day moving average price of $0.65 and a two-hundred day moving average price of $0.46. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The company has a market capitalization of $729.28 million, a PE ratio of -9.42 and a beta of 0.69.

Insider Transactions at Senseonics

In other news, CEO Timothy T. Goodnow purchased 315,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was bought at an average cost of $0.31 per share, with a total value of $97,650.00. Following the purchase, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Frederick T. Sullivan acquired 124,933 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the purchase, the chief financial officer now directly owns 2,478,844 shares in the company, valued at $941,960.72. This represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in Senseonics in the 4th quarter valued at approximately $26,000. HighTower Advisors LLC acquired a new stake in Senseonics in the 4th quarter valued at approximately $32,000. Cubist Systematic Strategies LLC grew its holdings in Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares during the last quarter. Ridgecrest Wealth Partners LLC acquired a new stake in Senseonics in the 4th quarter valued at approximately $60,000. Finally, FMR LLC grew its holdings in Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after buying an additional 167,970 shares during the last quarter. 12.36% of the stock is owned by institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.